Revelation Biosciences, Inc. (REVB)
| Previous Close | 1.9900 |
| Open | 2.0400 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 1.9950 - 2.0800 |
| 52 Week Range | 1.7800 - 36.9000 |
| Volume | |
| Avg. Volume | 126,293 |
| Market Cap | 3.315M |
| Beta (5Y Monthly) | 0.17 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.5300 |
| Earnings Date | Aug 09, 2024 - Aug 13, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 18.70 |
Business WireRevelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2024
SAN DIEGO, May 10, 2024--Revelation Biosciences, Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, today reported its three months ended March 31, 2024 financial results.
Business WireRevelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2023
SAN DIEGO, March 22, 2024--Revelation Biosciences, Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, today reported its three and twelve months ended December 31, 2023 financial results.
Business WireRevelation Biosciences Inc. Gives Oral Presentation at Advances in Critical Care Nephrology (AKI & CRRT 2024)
SAN DIEGO, March 13, 2024--Revelation Biosciences Inc. (NASDAQ: REVB) (the "Company" or "Revelation") a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, announced today new preclinical data on the potential therapeutic benefit of Gemini for the prevention of acute kidney injury (AKI) that was presented at the International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024) taking place
